Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Triple Negative Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Barts Cancer Institute, Centre of Experimental Cancer Medicine, London, United Kingdom
Contact: Study coordinator (Peter Schmid, MD PhD, FRCP) · p.schmid@qmul.ac.uk · +44(0)20 7882 8764
Barts Health NHS Trust, London, United Kingdom

Study leads

Peter Schmid, MD PhD, FRCP
Study Director
Queen Mary University of London

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Breast Neoplasms · Breast Cancer · Breast Tumors

Abroad (travel likely)RecruitingPHASE2

Birmingham, United States · Scottsdale, United States

Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel

Triple Negative Breast Cancer Metastatic

Abroad (travel likely)RecruitingPHASE2

Novara, Italy · Bergamo, Italy

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

Breast Cancer · Breast Cancer Female · Metastatic Triple-Negative Breast Carcinoma

Abroad (travel likely)RecruitingPHASE2

Miami, United States · Boston, United States

Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

Soft-tissue Sarcoma · Triple Negative Breast Cancer · Non-small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Orange, United States